Clinical characteristics and outcome of lung cancer in patients with fibrosing interstitial lung disease

BMC Pulmonary Medicine

Table 1 Baseline characteristics of patients with interstitial lung disease and lung cancer at lung cancer diagnosis

Characteristic	Total (n = 163)	IPF-LC (n = 92)	Non-IPF-LC (n = 71)	p Value
Type of ILD
IPF	92 (56.4)	92 (100.0)	0 (0.0)
Unclassifiable	54 (33.1)	0 (0.0)	54 (76.1)
CTD-ILD	0 (0.0)	0 (0.0)	14 (82.4)
NSIP	0 (0.0)	0 (0.0)	2 (11.8)
Chronic HP	0 (0.0)	0 (0.0)	1 (5.89)
Age, years	70.4 ± 7.3	70.5 ± 7.4	70.2 ± 7.2	0.827
Male	151 (92.6)	85 (92.4)	66 (93.0)	0.899
BMI, kg/m²	24.4 ± 3.1	24.4 ± 2.8	24.4 ± 3.5	0.956
Ever-smoker	149 (91.4)	84 (91.3)	65 (91.5)	0.827
Pulmonary function test
FVC (predicted), % (n = 161)	76.6 ± 16.8	76.5 ± 16.4	76.9 ± 17.5	0.884
FEV1 (predicted), % (n = 161)	81.2 ± 15.8	80.9 ± 15.2	81.5 ± 16.7	0.812
TLC (predicted), % (n = 81)	79.6 ± 13.4	79.3 ± 12.8	80.10 ± 14.47	0.800
DLco (predicted), % (n = 150)	55.7 ± 17.6	54.5 ± 17.7	57.39 ± 17.45	0.319
Laboratory data
KL-6 ≥ 1000 U/mL (n = 117)	32 (27.4)	20 (28.6)	12 (25.5)	0.718
Type of LC
NSCLC	141 (86.5)	81 (88.0)	60 (84.5)	0.512
Adenocarcinoma	74 (52.5)	43 (53.1)	31 (51.7)	0.867
Squamous cell carcinoma	64 (45.4)	35 (43.2)	29 (48.3)	0.546
Others^a	3 (2.1)	3 (3.7)	0 (0.0)	0.261
SCLC	22 (13.5)	11 (12.0)	11 (15.5)	0.512

Data are expressed as mean ± standard deviation for continuous variables and number (percentage) for categorical variables. ILD, interstitial lung disease; IPF, idiopathic progressive fibrosis; CTD, connective tissue disease; HP, hypersensitivity pneumonitis; NSIP, nonspecific interstitial pneumonia; BMI, body mass index; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s; TLC, total lung capacity; DLco, diffusing capacity for carbon monoxide; KL-6, Krebs von den Lungen-6; IS, immunosuppressants, LC; lung cancer, NSCLC; non-small cell lung cancer; SCLC, small cell lung cancer
^a Other histological types include large cell carcinoma

ISSN: 1471-2466